Your browser doesn't support javascript.
loading
Questions regarding the safety and duration of immunity following live yellow fever vaccination.
Amanna, Ian J; Slifka, Mark K.
Affiliation
  • Amanna IJ; a Najít Technologies, Inc. , Beaverton , OR , USA.
  • Slifka MK; b Division of Neuroscience, Oregon National Primate Research Center, Department of Molecular Microbiology and Immunology , Oregon Health & Science University , Beaverton , OR , USA.
Expert Rev Vaccines ; 15(12): 1519-1533, 2016 12.
Article in En | MEDLINE | ID: mdl-27267203
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yellow Fever / Immunization, Secondary / Yellow Fever Vaccine Type of study: Guideline Limits: Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yellow Fever / Immunization, Secondary / Yellow Fever Vaccine Type of study: Guideline Limits: Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido